Biological actions of the incretins GIP and GLP-1 and therapeutic perspectives in patients with type 2 diabetes

This publication has 47 references indexed in Scilit:

• Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Sulfonylurea-Treated Patients With Type 2 Diabetes
  Diabetes Care, 2004
• GLP‐1 receptor agonists are growth and differentiation factors for pancreatic islet beta cells
  Diabetes/Metabolism Research and Reviews, 2003
• GIF biology and fat metabolism
  Life Sciences, 1999
• Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men.
  International Journal of Obesity, 1999
• Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
  Journal of Clinical Investigation, 1998
• Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus.
  Journal of Clinical Investigation, 1993
• Insulinotropic Action of Glucagonlike Peptide-I-(7–37) in Diabetic and Nondiabetic Subjects
  Diabetes Care, 1992
• GLUCAGON-LIKE PEPTIDE-1 7-36: A PHYSIOLOGICAL INCRETIN IN MAN
  Published by Elsevier ,1987
• Oral Glucose Augmentation of Insulin Secretion
  Journal of Clinical Investigation, 1978
• Entero-insular axis
  Archives of internal medicine (1960), 1969